Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 7, 2013; 19(45): 8168-8180
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8168
How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?
Enzo Ierardi, Floriana Giorgio, Giuseppe Losurdo, Alfredo Di Leo, Mariabeatrice Principi
Enzo Ierardi, Floriana Giorgio, Giuseppe Losurdo, Alfredo Di Leo, Mariabeatrice Principi, Division of Gastroenterology, Department of Emergency and Organ Transplantation, 70124 Bari, Italy
Author contributions: Ierardi E, Di Leo A and Principi M designed the study, revised the manuscript, and approved the final version; Losurdo G and Giorgio F collected the data and revised the final version before approval.
Correspondence to: Enzo Ierardi, Professor, Division of Gastroenterology, Department of Emergency and Organ Transplantation, Viale Pinto, 70124 Bari, Italy. enzo.ierardi@fastwebnet.it
Telephone: +39-80-5592577 Fax: +39-80-5593088
Received: September 23, 2013
Revised: October 18, 2013
Accepted: November 3, 2013
Published online: December 7, 2013
Processing time: 85 Days and 15.8 Hours
Abstract

Therapeutic management of Helicobacter pylori (H. pylori) remains an unsolved issue. Indeed, no therapeutic regimen is able to cure the infection in all treated patients, and in many the infection persists despite the administration of several consecutive standard therapies. Although antibiotic resistance reports describe alarming results, the outcome of therapeutic regimens does not seem to parallel this scenario in most cases, since a successful performance is often reached in more than 80% of cases. However, the phenomenon of increasing antibiotic resistance is being closely studied, and the results show controversial aspects even in the same geographic area. For the continents of Europe, America, Asia, Africa, and Oceania, minimal and maximal values of resistance to the main antibiotics (clarithromycin, amoxicillin, metronidazole, and levofloxacin) feature wide ranges in different countries. The real enigma is therefore linked to the several different therapeutic regimens, which show results that often do not parallel the in vitro findings even in the same areas. A first aspect to be emphasized is that some regimens are limited by their use in very small geographic districts. Moreover, not all therapeutic trials have considered bacterial and host factors affecting the therapeutic outcome. The additional use of probiotics may help to reduce adverse events, but their therapeutic impact is doubtful. In conclusion, the “ideal therapy”, paradoxically, appears to be a “utopia”, despite the unprecedented volume of studies in the field and the real breakthrough in medical practice made by the discovery and treatment of H. pylori. The ample discrepancies observed in the different areas do not encourage the development of therapeutic guidelines that could be valid worldwide. On these bases, one of the main challenges for the future might be identifying a successful solution to overcome antibiotic resistances. In this context, geography must be considered a relevant matter.

Keywords: Helicobacter pylori; Antibiotic resistance; Geography; Therapeutic regimens; Therapeutic outcome

Core tip: The present topic outlines the main data regarding antibiotic resistances, paying particular attention to the discrepant results obtained in different geographic areas worldwide, and even in the same districts. Discordances between in vitro and in vivo studies are detailed and the possible factors explaining this phenomenon are analyzed. Finally, the challenge for the future of devising a successful solution to overcome antibiotic resistances is highlighted, and geography is suggested as a relevant matter.